Johnson & Johnson COVID vaccinations can restart, U.S. health regulators said Friday, after the shots' rollout was paused due to worries over blood clotting.
Health authorities in the United States on April 14 proposed a halt on the vaccine following instances of severe blood clots among a handful of the millions of Americans who received the vaccine.
The news came shortly after an expert panel recommended lifting the pause because the shots' benefits exceeded possible dangers.
"We have concluded that the known and potential benefits of the Janssen COVID-19 vaccine outweigh its known and potential risks in individuals 18 years of age and older," said Janet Woodcock, head of Food and Drug Administration in a joint statement with the Centers for Disease Control and Prevention (CDC).
ALSO READ:
Single-Dose Johnson & Johnson Vaccine Cleared for Emergency Use in PH
CDC head Rochelle Walensky said "exceptionally rare events" of clotting were identified, adding that regulators will continue to monitor the rollout of the vaccines.
According to data presented Friday, of 3.9 million women who got the Johnson & Johnson shot, 15 developed serious blood clots and three died.
The majority of the confirmed cases, 13 of the 15, were aged under 50 years old. There were no reported cases among men.
Europe's medicines regulator said Tuesday that blood clots should be listed as a "very rare" side effect of Johnson & Johnson's coronavirus vaccine.
The regulator said its safety committee "concluded that a warning about unusual blood clots with low blood platelets should be added to the product information" for the J&J shot.
MORE ON VACCINES:
Essential Workers Could Get Vaccines by May: Official
How COVID Vaccines Work and Why You Should Get One
The Blood Clot Risk From AstraZeneca's Vaccine is This Rare
How Soon Can a Recovered COVID Patient Get a Vaccine?
Reportr is now on Quento. Download the app on iOS and Android or visit the Quento website for more articles and videos from Reportr and your favorite websites.
